Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$9.56 USD
-0.03 (-0.31%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $9.55 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Lexeo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -66.39 | -59.28 | NA | NA | NA |
Depreciation/Amortization & Depletion | 0.27 | 0.12 | NA | NA | NA |
Net Change from Assets/Liabilities | 1.48 | 1.79 | NA | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | NA | NA | NA |
Other Operating Activities | 5.15 | 2.81 | NA | NA | NA |
Net Cash From Operating Activities | -59.50 | -54.56 | NA | NA | NA |
Property & Equipment | -0.12 | -0.67 | NA | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | NA | NA | NA |
Investments | 0.00 | 0.00 | NA | NA | NA |
Other Investing Activities | -0.05 | -0.23 | NA | NA | NA |
Net Cash from Investing Activities | -0.17 | -0.90 | NA | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 100.30 | 0.35 | NA | NA | NA |
Issuance (Repayment) of Debt | 3.58 | -0.16 | NA | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | NA | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | NA | NA | NA |
Other Financing Activities | -0.09 | 0.00 | NA | NA | NA |
Net Cash from Financing Activities | 103.79 | 0.19 | NA | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | NA | NA | NA |
Net Change In Cash & Equivalents | 44.13 | -55.27 | NA | NA | NA |
Cash at Beginning of Period | 80.59 | 135.86 | NA | NA | NA |
Cash at End of Period | 124.72 | 80.59 | NA | NA | NA |
Diluted Net EPS | -12.40 | -36.36 | NA | NA | NA |
Fiscal Year End for Lexeo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -42.92 | -21.68 | -66.39 | -52.21 | -32.10 |
Depreciation/Amortization & Depletion | 0.15 | 0.48 | 0.27 | 1.35 | 0.12 |
Net Change from Assets/Liabilities | 1.75 | 4.01 | 1.48 | 2.83 | -1.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.00 | 2.33 | 5.15 | 2.51 | 2.14 |
Net Cash From Operating Activities | -35.02 | -14.87 | -59.50 | -45.52 | -31.57 |
Property & Equipment | -0.40 | -0.19 | -0.12 | -0.04 | -0.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -0.01 | -0.01 | -0.05 | -0.05 | 0.00 |
Net Cash from Investing Activities | -0.41 | -0.19 | -0.17 | -0.09 | -0.04 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 89.13 | 88.76 | 100.30 | 0.05 | 0.02 |
Issuance (Repayment) of Debt | -0.18 | -0.11 | 3.58 | 3.68 | -0.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.09 | -0.01 | 0.00 |
Net Cash from Financing Activities | 88.95 | 88.65 | 103.79 | 3.72 | -0.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 53.52 | 73.59 | 44.13 | -41.89 | -31.80 |
Cash at Beginning of Period | 124.72 | 124.72 | 80.59 | 80.59 | 80.59 |
Cash at End of Period | 178.23 | 198.31 | 124.72 | 38.70 | 48.79 |
Diluted Net EPS | -0.64 | -0.77 | -0.86 | -12.36 | -8.30 |